Uta Griesenbach, Eric W.F.W. Alton, Department of Gene Therapy, Faculty of Medicine ... proof-of-principle for gene transfer into the cystic fibrosis (CF) lung. It is currently unknown whether ...

A Wicklow mother is among a concerned group of parents who are calling for individual trials of the modulator therapies for ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Sophie would make a world record for being the first man or woman with cystic fibrosis to row across the Atlantic, while at ...

Some people with cystic fibrosis still do not have access to the life-changing modulator therapy drugs, despite wider EMA ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Boehringer Ingelheim (BI) and the UK Cystic Fibrosis Gene Therapy Consortium announced a global collaboration to develop a first-in-class, long-term therapy for patients with cystic fibrosis (CF).

Cystic fibrosis is a genetic disorder that affects various organs, including the lungs and digestive system. Medications are important for managing symptoms, but there is currently no cure for the ...

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

Analyst Matthew Caufield of H.C. Wainwright reiterated a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report), retaining the price ...